ClinicalTrials.gg
CompletedNCT03832114Updated Jan 30, 2024Results posted

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

A Phase 2 interventional study of LNP023 in Glomerulonephritis, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Glomerulonephritis with a site in France — 5 open to participants now, 8 under way, 5 of them phase 3. Glomerulonephritis · France.

Enrollment
11th of 12
27 · median 137
Started
2019
the only one that year
Phase 2
4 of 13
2 open now
Registered
4th of 13
by date
Lead sponsor
5 of 13
Novartis Pharmaceuticals

Among the 13 studies in Glomerulonephritis with a site in France, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 2, and was the 4th registered.

Glomerulonephritis

115 studies on the registry are indexed under Glomerulonephritis; 32 are open to participants now.

Browse Glomerulonephritis studies →

Open to participants now

5 of the 13 studies in Glomerulonephritis with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 26 Glomerulonephritis studies recruiting now, 15 (58%) set no upper age limit and 6 (23%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Glomerulonephritis with a site in France, or all of them as a file.
02

Study summary

The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).

03

Conditions studied

  • Glomerulonephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Cohort A and B:

  • Written must be obtained before any assessment is performed
  • Male and female patients between the ages of 18 to 65 (inclusive) at screening
  • C3G patients wit proteinuria
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study
  • At screening and baseline visits, patients must weigh at least 35 kg
  • Supine vital signs should be within the following ranges :

oral body temperature between 35.0-37.5 °C systolic blood pressure, 80-170 mm Hg diastolic blood pressure, 50-105 mm Hg pulse rate, 45 - 100 bpm

.

Inclusion Criteria for Cohort A:

  • Estimated (using the CKD-EPI formula) or measured GFR ≥30 mL/min per 1.73 m2 for patients on a maximum recommended or maximum tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
  • UPCR ≥ 100 mg/mmol (equivalent to ≥ 1 g/24h total urinary protein excretion)
  • Prior to entry, all patients must have been on supportive care including a maximally tolerated dose of ACEi or ARB for at least 30 days.

Inclusion Criteria for Cohort B:

  • No histological/laboratory/clinical signs of allorejection
  • If applicable, induction treatment after allotransplantation needs to be completed >30 days before inclusion.
  • Transplantation of a kidney allograft >90 days before inclusion
  • Patients need to be on a stable dose of regimen prior to inclusion. Any approved treatments are allowed for this purpose.

Exclusion Criteria for Cohort A and B:

  • Use of other drugs at the time of enrollment, or within 5 half-lives of randomization, or within 30 days, whichever is longer; or longer if required by local regulations
  • A history of abnormalities,
  • Known family history or known presence of long syndrome or Torsades de Pointes
  • Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of the study
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of child bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing and for 1 week after stopping of investigational drug.
  • History of immunodeficiency diseases, or a positive test result.
  • Chronic infection with (HBV) or (HCV).
  • Patients who cannot receive vaccinations against N. meningitidis, S. pneumoniae, or H. influenzae
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Cohort A - no kidney transplant

    C3G patients who have not received a kidney transplant and have reduced C3 blood levels.

    Drug: LNP023

  • Experimental
    Cohort B - kidney transplant

    C3G patients who have received a kidney transplant and have C3G recurrence.

    Drug: LNP023

Interventions

  • DrugLNP023

    Increasing doses of LNP023 up to 200 mg.

06

What researchers measure

Primary outcomes

  1. Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR)

    Change in proteinuria assessed by ratio to baseline of UPCR derived from 24h urine collection

    Time frame: Week 12

  2. Cohort B: Change From Baseline in C3 Deposit

    Histopathological changes in kidney biopsies as assessed by change from baseline in C3 Deposit Score (based on immunofluorescence microscopy)

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in Urine Protein Creatinine Concentration Ratio (UPCR)

    Ratio to baseline UPCR derived from 24 hour urine collection

    Time frame: Week 12: Day 84

  2. Change From Baseline in Urine Protein (UP) Excretion

    Ratio to baseline UP excretion derived from 24 hour urine collection

    Time frame: Week 12: Day 84

  3. Change From Baseline in Urine Albumin Creatinine Concentration Ratio (UACR) Excretion

    Ratio to baseline UACR excretion derived from 24 hour urine collection

    Time frame: Week 12: Day 84

  4. Change From Baseline Change in Urinary Albumin (UA) Excretion

    Ratio to baseline UA excretion derived from 24 hour urine collection

    Time frame: Week 12: Day 84

  5. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Effect of LNP023 on estimated glomerular filtration rate (eGFR)

    Time frame: Day 84

  6. Change From Baseline in Serum Creatinine

    The effect of LNP023 on renal function - serum creatinine

    Time frame: Week 12: Day 84

  7. Change From Baseline in Creatinine Clearance

    The effect of LNP023 on renal function - creatinine clearance

    Time frame: Week 12: Day 84

  8. Number of Patients With Hematuria

    The effect of LNP023 on renal function - hematuria

    Time frame: Week 12: Day 84

  9. Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) First Morning Void

    Ratio to baseline of UPCR reduction derived from total cumulative urinary excretion first morning void

    Time frame: Week 9: Day 64

  10. Change From Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR) First Morning Void

    UACR reduction derived from total cumulative urinary excretion first morning void

    Time frame: Week 9: Day 64

  11. Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUClast (AUC)

    The area under the plasma concentration-time curve calculated from time zero to the last quantifiable concentration point (hr\*ng/mL)

    Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)

  12. Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUCtau (AUC)

    The area under the plasma concentration-time curve calculated to the end of the dosing interval (hr\*ng/mL)

    Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)

  13. Observed Maximum Concentration After Drug Administration (Cmax)

    The observed maximum plasma concentration (ng/mL)

    Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)

  14. Observed Minimum Concentration After Drug Administration (Ctrough)

    The concentration that is just prior to the beginning of, or at the end, of a dosing interval (ng/mL)

    Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)

  15. Time to Reach the Maximum Plasma Concentration (Tmax)

    The time to reach peak or maximum concentration (hr)

    Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)

  16. Summary of Change From Baseline Complement C3 Biomarker in Serum

    To assess the effect of LNP023 on alternative complement pathway hyperactivity.

    Time frame: Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84

  17. Ratio to Baseline Summary of Plasma Bb

    To assess the relationship between LNP023 dose and pharmacodynamic biomarker levels of blood Bb

    Time frame: Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84

07

Results

Posted Jul 8, 2022

Participant flow

A total of 27 patients (16 patients in Cohort A and 11 patients in Cohort B) were enrolled and treated in the treatment period 1. All 27 patients completed the study and there were no patients who discontinued the study.

Run-in Phase
Participant flow — Run-in Phase
MilestoneCohort A: Run-In PhaseCohort B: Run-In PhaseCohort A: Dose Escalation/LNP023 Treatment 200 mg b.i.dCohort B - Dose Escalation/LNP023 Treatment 200 mg b.i.d
Started161100
Completed161100
Not completed0000
Dose Escalation/200mg b.i.d Treatment
Participant flow — Dose Escalation/200mg b.i.d Treatment
MilestoneCohort A: Run-In PhaseCohort B: Run-In PhaseCohort A: Dose Escalation/LNP023 Treatment 200 mg b.i.dCohort B - Dose Escalation/LNP023 Treatment 200 mg b.i.d
Started001611
Completed001611
Not completed0000

Outcome measures

PrimaryCohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR)

Change in proteinuria assessed by ratio to baseline of UPCR derived from 24h urine collection

Time frame:
Week 12
Reported as:
Geometric mean · ratio
Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR)
ratioCohort A - no Kidney Transplant
Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR)0.55 (0.46 to 0.65)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.0003 · Mean difference (final values): 0.55 · 80% CI 0.46 to 0.65
PrimaryCohort B: Change From Baseline in C3 Deposit

Histopathological changes in kidney biopsies as assessed by change from baseline in C3 Deposit Score (based on immunofluorescence microscopy)

Time frame:
Week 12
Reported as:
Median · Percentage change
Cohort B: Change From Baseline in C3 Deposit
Percentage changeCohort B - Kidney Transplant
Cohort B: Change From Baseline in C3 Deposit-2.50 (-3.75 to -0.75)
Statistical analysis
  • Cohort B - Kidney Transplant · Wilcoxon (Mann-Whitney) · p = 0.0313 · Median difference (final values): -2.50 · 80% CI -3.75 to -0.75
SecondaryChange From Baseline in Urine Protein Creatinine Concentration Ratio (UPCR)

Ratio to baseline UPCR derived from 24 hour urine collection

Time frame:
Week 12: Day 84
Reported as:
Geometric mean · ratio
Change From Baseline in Urine Protein Creatinine Concentration Ratio (UPCR)
ratioCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline in Urine Protein Creatinine Concentration Ratio (UPCR)0.55 (0.46 to 0.65)0.79 (0.49 to 1.28)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.0003 · Mean difference (final values): 0.55 · 80% CI 0.46 to 0.65
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.4766 · Mean difference (final values): 0.79 · 80% CI 0.49 to 1.28
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model of Repeated Measures (MMRM) · p = 0.0002 · Mean difference (final values): 0.59 · 80% CI 0.51 to 0.69
SecondaryChange From Baseline in Urine Protein (UP) Excretion

Ratio to baseline UP excretion derived from 24 hour urine collection

Time frame:
Week 12: Day 84
Reported as:
Geometric mean · ratio
Change From Baseline in Urine Protein (UP) Excretion
ratioCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline in Urine Protein (UP) Excretion0.57 (0.47 to 0.68)1.00 (0.75 to 1.33)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measures (MMRM · p = 0.0011 · Mean difference (final values): 0.57 · 80% CI 0.47 to 0.68
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.9998 · Mean difference (final values): 1.00 · 80% CI 0.75 to 1.33
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.0016 · Mean difference (final values): 0.66 · 80% CI 0.56 to 0.77
SecondaryChange From Baseline in Urine Albumin Creatinine Concentration Ratio (UACR) Excretion

Ratio to baseline UACR excretion derived from 24 hour urine collection

Time frame:
Week 12: Day 84
Reported as:
Geometric mean · ratio
Change From Baseline in Urine Albumin Creatinine Concentration Ratio (UACR) Excretion
ratioCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline in Urine Albumin Creatinine Concentration Ratio (UACR) Excretion0.55 (0.47 to 0.64)0.61 (0.30 to 1.27)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measures (MRM) · p = <0.0001 · Mean difference (final values): 0.55 · 80% CI 0.47 to 0.64
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.3707 · Mean difference (final values): 0.61 · 80% CI 0.30 to 1.27
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.0002 · Mean difference (final values): 0.60 · 80% CI 0.51 to 0.71
SecondaryChange From Baseline Change in Urinary Albumin (UA) Excretion

Ratio to baseline UA excretion derived from 24 hour urine collection

Time frame:
Week 12: Day 84
Reported as:
Geometric mean · ratio
Change From Baseline Change in Urinary Albumin (UA) Excretion
ratioCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline Change in Urinary Albumin (UA) Excretion0.57 (0.47 to 0.70)0.81 (0.67 to 0.98)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.0018 · Mean difference (final values): 0.57 · 80% CI 0.47 to 0.70
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.1632 · Mean difference (final values): 0.81 · 80% CI 0.67 to 0.98
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model Repeated Measure (MMRM) · p = 0.0040 · Mean difference (final values): 0.67 · 80% CI 0.57 to 0.79
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR)

Effect of LNP023 on estimated glomerular filtration rate (eGFR)

Time frame:
Day 84
Reported as:
Mean · ml/min
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
ml/minCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)2.59 (0.12 to 5.06)-0.61 (-3.36 to 2.15)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model of Repeated Measures (MMRM) · p = 0.1795 · Mean difference (final values): 2.59 · 80% CI 0.12 to 5.06
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.7763 · Mean difference (final values): -0.61 · 0.7763% CI -3.36 to 2.15
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.3754 · Mean difference (final values): 1.32 · 80% CI -0.59 to 3.22
SecondaryChange From Baseline in Serum Creatinine

The effect of LNP023 on renal function - serum creatinine

Time frame:
Week 12: Day 84
Reported as:
Mean · mmol/L
Change From Baseline in Serum Creatinine
mmol/LCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline in Serum Creatinine-5.04 (-9.36 to -0.72)7.17 (-1.79 to 16.13)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measuers (MMRM) · p = 0.1364 · Mean difference (final values): -5.04 · 80% CI -9.36 to -0.72
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.3038 · Mean difference (final values): 7.17 · 80% CI -1.79 to 16.13
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.8352 · Mean difference (final values): -0.77 · 80% CI -5.56 to 4.01
SecondaryChange From Baseline in Creatinine Clearance

The effect of LNP023 on renal function - creatinine clearance

Time frame:
Week 12: Day 84
Reported as:
Geometric mean · mL/min
Change From Baseline in Creatinine Clearance
mL/minCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline in Creatinine Clearance1.07 (0.99 to 1.17)1.20 (0.83 to 1.72)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.2752 · Mean difference (final values): 1.07 · 80% CI 0.99 to 1.17
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.476 · Mean difference (final values): 1.20 · 80% CI 0.83 to 1.72
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.1963 · Mean difference (final values): 1.10 · 80% CI 1.00 to 1.20
SecondaryNumber of Patients With Hematuria

The effect of LNP023 on renal function - hematuria

Time frame:
Week 12: Day 84
Reported as:
Count of participants · Participants
Number of Patients With Hematuria
ParticipantsCohort A - no Kidney TransplantCohort B - Kidney Transplant
Week 12: Day 84: <9 rbc/hpf n (%)103
Week 12: Day 84: >= 9 to =<50 rbc/hpf n (%)00
Week 12: Day 84: >50 rbc/hpf n (%)00
SecondaryChange From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) First Morning Void

Ratio to baseline of UPCR reduction derived from total cumulative urinary excretion first morning void

Time frame:
Week 9: Day 64
Reported as:
Geometric mean · ratio
Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) First Morning Void
ratioCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) First Morning Void0.56 (0.48 to 0.65)0.99 (0.76 to 1.28)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = <0.0001 · Mean difference (final values): 0.56 · 80% CI 0.48 to 0.65
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.9544 · Mean difference (final values): 0.99 · 80% CI 0.76 to 1.28
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = <.0001 · Mean difference (final values): 0.64 · 80% CI 0.56 to 0.72
SecondaryChange From Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR) First Morning Void

UACR reduction derived from total cumulative urinary excretion first morning void

Time frame:
Week 9: Day 64
Reported as:
Geometric mean · g/mol
Change From Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR) First Morning Void
g/molCohort A - no Kidney TransplantCohort B - Kidney Transplant
Change From Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR) First Morning Void0.59 (0.50 to 0.69)0.87 (0.60 to 1.26)
Statistical analysis
  • Cohort A - no Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = <.0001 · Mean difference (final values): 0.59 · 80% CI 0.50 to 0.69
  • Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.6209 · Median difference (final values): 0.87 · 80% CI 0.60 to 1.26
  • Cohort A - no Kidney Transplant vs Cohort B - Kidney Transplant · Mixed Model Repeated Measures (MMRM) · p = 0.0002 · Mean difference (final values): 0.63 · 80% CI 0.54 to 0.73
SecondaryPharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUClast (AUC)

The area under the plasma concentration-time curve calculated from time zero to the last quantifiable concentration point (hr\*ng/mL)

Time frame:
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Reported as:
Mean · hr*ng/mL
Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUClast (AUC)
hr*ng/mLCohort A - no Kidney Transplant - LNP023 10mg b.i.d.Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d.Cohort B - Kidney Transplant - LNP023 10mg b.i.d.Cohort B - Kidney Transplant - LNP023 25 mg b.i.d.Cohort B - Kidney Transplant - LNP023 100 mg b.i.d.Cohort B - Kidney Transplant - LNP023 200 mg b.i.d.
Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUClast (AUC)3690 ± 6935790 ± 163013200 ± 441020300 ± 81804560 ± 20607880 ± 383019600 ± 1210028100 ± 15900
SecondaryPharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUCtau (AUC)

The area under the plasma concentration-time curve calculated to the end of the dosing interval (hr\*ng/mL)

Time frame:
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Reported as:
Mean · hr*ng/mL
Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUCtau (AUC)
hr*ng/mLCohort A - no Kidney Transplant - LNP023 10mg b.i.d.Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d.Cohort B - Kidney Transplant - LNP023 10mg b.i.d.Cohort B - Kidney Transplant - LNP023 25 mg b.i.d.Cohort B - Kidney Transplant - LNP023 100 mg b.i.d.Cohort B - Kidney Transplant - LNP023 200 mg b.i.d.
Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUCtau (AUC)5020 ± 11107970 ± 225017800 ± 580026900 ± 109006300 ± 300010700 ± 531026600 ± 1650037700 ± 22000
SecondaryObserved Maximum Concentration After Drug Administration (Cmax)

The observed maximum plasma concentration (ng/mL)

Time frame:
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Reported as:
Mean · ng/mL
Observed Maximum Concentration After Drug Administration (Cmax)
ng/mLCohort A - no Kidney Transplant - LNP023 10mg b.i.d.Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d.Cohort B - Kidney Transplant - LNP023 10mg b.i.d.Cohort B - Kidney Transplant - LNP023 25 mg b.i.d.Cohort B - Kidney Transplant - LNP023 100 mg b.i.d.Cohort B - Kidney Transplant - LNP023 200 mg b.i.d.
Observed Maximum Concentration After Drug Administration (Cmax)637 ± 97.1941 ± 2782270 ± 8053600 ± 1230713 ± 2921280 ± 5523250 ± 17904700 ± 2200
SecondaryObserved Minimum Concentration After Drug Administration (Ctrough)

The concentration that is just prior to the beginning of, or at the end, of a dosing interval (ng/mL)

Time frame:
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Reported as:
Mean · ng/mL
Observed Minimum Concentration After Drug Administration (Ctrough)
ng/mLCohort A - no Kidney Transplant - LNP023 10mg b.i.d.Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d.Cohort B - Kidney Transplant - LNP023 10mg b.i.d.Cohort B - Kidney Transplant - LNP023 25 mg b.i.d.Cohort B - Kidney Transplant - LNP023 100 mg b.i.d.Cohort B - Kidney Transplant - LNP023 200 mg b.i.d.
Observed Minimum Concentration After Drug Administration (Ctrough)314 ± 133519 ± 1331090 ± 4081480 ± 653417 ± 237644 ± 3251650 ± 10102180 ± 1610
SecondaryTime to Reach the Maximum Plasma Concentration (Tmax)

The time to reach peak or maximum concentration (hr)

Time frame:
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Reported as:
Median · hr
Time to Reach the Maximum Plasma Concentration (Tmax)
hrCohort A - no Kidney Transplant - LNP023 10mg b.i.d.Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d.Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d.Cohort B - Kidney Transplant - LNP023 10mg b.i.d.Cohort B - Kidney Transplant - LNP023 25 mg b.i.d.Cohort B - Kidney Transplant - LNP023 100 mg b.i.d.Cohort B - Kidney Transplant - LNP023 200 mg b.i.d.
Time to Reach the Maximum Plasma Concentration (Tmax)2.00 (0.800 to 6.00)2.00 (0.900 to 4.00)2.00 (0.500 to 4.00)2.00 (1.00 to 4.00)2.00 (1.00 to 4.00)2.00 (1.00 to 6.00)2.00 (1.00 to 4.00)2.00 (1.00 to 4.00)
SecondarySummary of Change From Baseline Complement C3 Biomarker in Serum

To assess the effect of LNP023 on alternative complement pathway hyperactivity.

Time frame:
Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
Reported as:
Mean · g/L
Summary of Change From Baseline Complement C3 Biomarker in Serum
g/LCohort A - no Kidney TransplantCohort B - Kidney Transplant
Day 1 pre-dose0.0 ± 0.060.0 ± 0.12
Day 7 - pre-dose0.1 ± 0.100.2 ± 0.22
Day 14 - pre-dose0.3 ± 0.170.4 ± 0.29
Day 21 - pre-dose0.5 ± 0.250.4 ± 0.33
Day 28 - pre-dose0.5 ± 0.290.4 ± 0.27
Day 36 - pre-dose0.6 ± 0.280.4 ± 0.32
Day 64 - pre-dose0.6 ± 0.270.4 ± 0.26
Day 84 - pre-dose0.6 ± 0.300.5 ± 0.26
SecondaryRatio to Baseline Summary of Plasma Bb

To assess the relationship between LNP023 dose and pharmacodynamic biomarker levels of blood Bb

Time frame:
Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
Reported as:
Mean · Ratio of plasma Bb
Ratio to Baseline Summary of Plasma Bb
Ratio of plasma BbCohort A - no Kidney TransplantCohort B - Kidney Transplant
Day 1 pre-dose101.8 ± 45.18109.7 ± 34.08
Day 7 pre-dose102.4 ± 40.4783.6 ± 27.73
Day 14 pre-dose104.4 ± 43.3581.8 ± 39.34
Day 21 pre-dose97.0 ± 58.0666.4 ± 22.95
Day 28 pre-dose90.2 ± 46.2471.5 ± 29.52
Day 36 pre-dose102.5 ± 54.0665.9 ± 31.20
Day 64 pre-dose116.8 ± 59.7673.2 ± 29.62
Day 84 pre-dose116.6 ± 57.8576.3 ± 35.84

Adverse events

Collected over Adverse Events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of approximately 2 years, 2 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A - Run-in Phase0/16 (0%)0/16 (0%)0/16 (0%)
Cohort A - Dose Escalation Phase0/16 (0%)0/16 (0%)6/16 (37.5%)
Cohort A - LNP023 200mg b.i.d0/16 (0%)0/16 (0%)8/16 (50%)
Cohort B - Run-in Phase0/11 (0%)0/11 (0%)0/11 (0%)
Cohort B - Dose Escalation Phase0/11 (0%)0/11 (0%)5/11 (45.5%)
Cohort B - LNP023 200mg b.i.d0/11 (0%)2/11 (18.2%)6/11 (54.5%)
Most frequent serious events
Most frequent serious events
EventCohort A - Run-in PhaseCohort A - Dose Escalation PhaseCohort A - LNP023 200mg b.i.dCohort B - Run-in PhaseCohort B - Dose Escalation PhaseCohort B - LNP023 200mg b.i.d
OverdoseInjury, poisoning and procedural complications0/160/160/160/110/111/11
HyperkalaemiaMetabolism and nutrition disorders0/160/160/160/110/111/11
Most frequent other events
Showing 10 of 40
Most frequent other events
EventCohort A - Run-in PhaseCohort A - Dose Escalation PhaseCohort A - LNP023 200mg b.i.dCohort B - Run-in PhaseCohort B - Dose Escalation PhaseCohort B - LNP023 200mg b.i.d
HyperkalaemiaMetabolism and nutrition disorders0/160/160/160/110/112/11
HeadacheNervous system disorders0/160/160/160/112/110/11
Conjunctival hyperaemiaEye disorders0/160/160/160/111/110/11
DyspepsiaGastrointestinal disorders0/160/160/160/111/110/11
NauseaGastrointestinal disorders0/160/160/160/110/111/11
VomitingGastrointestinal disorders0/161/160/160/110/111/11
COVID-19Infections and infestations0/160/160/160/110/111/11
HordeolumInfections and infestations0/160/160/160/110/111/11
InfluenzaInfections and infestations0/160/160/160/110/111/11
NasopharyngitisInfections and infestations0/160/160/160/111/110/11

Baseline characteristics

For all analysis sets, patients were analyzed according to study drug received for Cohort A and B. Safety analysis set included all patients that received any study drug. PK analysis set included all patients with available PK data and no protocol deviations with relevant impact on PK data.

Age, Customized
Age, Customized(Years)Cohort A - no Kidney TransplantCohort B - Kidney TransplantTotal
Median22.0 (18 to 59)31.0 (18 to 70)24.0 (18 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A - no Kidney TransplantCohort B - Kidney TransplantTotal
Female639
Male10818
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A - no Kidney TransplantCohort B - Kidney TransplantTotal
American Indian or Alaska011
Black or African American011
White16925
Hispanic or Latino011
Not Hispanic or Latino16824
Not Reported022
08

Study locations

9 sites
  • Novartis Investigative Site
    Iowa City, Iowa 52242, United States
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Ranica, BG 24020, Italy
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    London, W12 0NN, United Kingdom
  • Novartis Investigative Site
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Apr 2021, 26 months.

Results were first posted in Jul 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2019
First posted
Feb 6, 2019
StartActual
Feb 20, 2019
Primary completionActual
Apr 23, 2021
CompletionActual
Apr 23, 2021
Results first posted
Jul 8, 2022
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03832114
Responsible party
Sponsor
First posted
Feb 6, 2019
Start date
Feb 20, 2019
Primary completion
Apr 23, 2021
Completion
Apr 23, 2021
Results posted
Jul 8, 2022
Last update
Jan 30, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion